KOSDAQBiotech & Pharma241820

Pcl

₩6,040 0.00%2026-10-02 close

Market Cap

₩16.8B

Turnover

₩0

Volume

0 shares

Shares out.

2.8M

PER

—

PBR

—

EPS

-₩16,917

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2024Q4–2025Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

PCL at a Crossroads: Halt and Receivership

In vitro diagnostics maker PCL received a KOSDAQ delisting resolution amid a collapse in sales, the revocation of its core product's approval, and clinical-trial falsification allegations, and is now under trading suspension while pursuing court receivership and a change-of-control sale simultaneously.

1
The KOSDAQ Market Committee resolved to delist the stock on September 5, 2025, and the company's injunction filing on October 2, 2025 has suspended the delisting procedures, including any liquidation trading.
2
Annual revenue plunged from about 37.2 billion won in 2022 to roughly 1.2 billion won in 2024, triggering failure to meet KOSDAQ's minimum sales requirement and administrative-issue designation.
3
The manufacturing approval for its core COVID-19 saliva self-test kit was revoked in December 2025 amid clinical-trial falsification allegations.
4
Court receivership proceedings and a change-of-control transaction via third-party share issuance and stake sale are proceeding in parallel.
5
Operating and net income turned narrowly positive in the third quarter of 2025, but the cumulative net result over the trailing four quarters remains deeply negative.

Business structure

Founded in 2008, PCL is an in vitro diagnostics (IVD) specialist that has developed proprietary multiplex, high-sensitivity immunodiagnostic technology used in blood-screening diagnostic products and point-of-care testing (POCT) platforms.

The company has stated that its SG Cap technology enabled what it describes as the world's first commercialization of a multiplex immunoassay for blood screening of high-risk viruses.

Most of its revenue has historically come from rapid diagnostic kit sales, most notably from COVID-19 test kit exports during the pandemic, which produced a temporary earnings spike.

The company holds patents filed in 30 countries related to its virus-detection technology and listed on KOSDAQ in 2017 under the technology special-listing track.

Peer and comparable companies cited in industry coverage include Seegene, Humasis, Intron Biotechnology, Access Bio, and Sugentech among Korea's IVD and molecular-diagnostics makers.

More recently, the company has discussed diversification opportunities, including talks with Myongji Hospital on building a smart blood bank and a plasma-derived medicinal product (PDMP) facility.

However, at an extraordinary shareholders meeting, the company added roughly 47 new business purposes, including consumer-goods distribution and advertising services, that appear unrelated to its core diagnostics business, raising questions about strategic direction.

On balance, PCL's underlying business has been tested severely as core-product revenue collapsed after the pandemic-driven demand surge faded.

Earnings trend

Quarterly revenue · Operating profit

₩400M-₩2.3B24Q3₩63,108,438-₩17.3B24Q4₩2B₩58,789,51925Q1₩1.7B-₩4.1B25Q2₩1.2B₩100M25Q3

RevenueOperating profit

Annual revenue · Operating profit

₩37.2B-₩8.2B2022₩8.4B-₩16.1B2023₩1.2B-₩27.1B2024

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2024Q3	₩400M	-₩2.3B	−607.8%
2024Q4	₩63,108,438	-₩17.3B	−27417.4%
2025Q1	₩2B	₩58,789,519	2.9%
2025Q2	₩1.7B	-₩4.1B	−247.5%
2025Q3	₩1.2B	₩100M	10.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩37.2B	-₩8.2B	-₩4B	−22.2%	−12.7%	161.4%
2023	₩8.4B	-₩16.1B	-₩20.3B	−191.4%	−57.2%	65.4%
2024	₩1.2B	-₩27.1B	-₩52.3B	−2175.4%	−735.5%	203.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05

Earnings analysis

On a confirmed-financials basis, PCL's annual revenue collapsed for three straight years, from about 37.2 billion won in 2022 to 8.4 billion won in 2023 and just 1.2 billion won in 2024.

Over the same period, the operating loss widened from 8.2 billion won to 16.1 billion won and then 27.1 billion won, with the operating margin deteriorating from -22.2% in 2022 to -191.4% in 2023 and -2,175.4% in 2024, reflecting the collapse of the revenue base itself.

Net loss attributable to controlling shareholders also grew sharply, from 4.0 billion won in 2022 to 20.3 billion won in 2023 and 52.3 billion won in 2024, while controlling-shareholder equity fell from 35.5 billion won in 2023 to just 7.1 billion won in 2024, indicating severe capital erosion.

On a quarterly basis, fourth-quarter 2024 revenue fell to roughly 63 million won, with an operating loss of 17.3 billion won and a controlling-shareholder net loss of 42.7 billion won concentrated in that single quarter, a period that coincided with the escalation of the clinical-trial falsification investigation and product-approval revocation process.

Results fluctuated through 2025: the first quarter (revenue of 2.0 billion won, operating profit of about 59 million won, net loss of 146 million won) and the third quarter (revenue of 1.2 billion won, operating profit of 127 million won, net profit of 206 million won) posted narrow gains, while the second quarter (revenue of 1.7 billion won, operating loss of 4.1 billion won, net loss of 4.5 billion won) reverted to a large loss.

As a result, the trailing four-quarter (Q4 2024 through Q3 2025) cumulative net loss attributable to controlling shareholders reached roughly 47.1 billion won, meaning individual quarters of narrow profitability have not reversed the cumulative trend.

Operating cash flow also worsened, from negative 1.0 billion won in 2022 to negative 4.8 billion won in 2023 and negative 15.8 billion won in 2024, suggesting continued reliance on external funding absent a recovery in sales.

Industry analysis

Korea's in vitro diagnostics industry is in a structural downturn in demand for rapid test kits following the end of pandemic-driven demand, with reports that even large companies that once exceeded 1 trillion won in annual sales during the pandemic have seen results deteriorate sharply.

A number of diagnostics and medical-device companies, similar to PCL, have reportedly been placed under KOSDAQ eligibility review for reasons including insufficient revenue, capital impairment, and audit-opinion issues.

The Korea Exchange plans to raise the minimum revenue threshold for maintaining a KOSDAQ listing in stages, from the current 3 billion won to 5 billion won in 2027, 7.5 billion won in 2028, and 10 billion won in 2029, while also progressively raising the minimum market-capitalization threshold starting in 2026, increasing the listing-maintenance burden on smaller biotech and diagnostics companies.

This tightening is widely seen as a response to the failure of many technology-track-listed IVD companies to normalize earnings after the pandemic ended.

Within the competitive landscape, molecular and antigen diagnostics companies are seeking survival through diversification into new applications such as non-infectious disease diagnostics, blood screening, and companion diagnostics, and PCL itself is in discussions on new collaborations involving a plasma-derived medicinal product (PDMP) facility and a smart blood bank.

That said, PCL faces regulatory issues specific to its core product (the approval revocation) layered on top of governance and accounting-credibility questions, placing it in a relatively more complex risk position even among peers experiencing similar revenue contraction.

Outlook

The company's path forward will largely hinge on two parallel restructuring tracks: court receivership and a change-of-control sale.

PCL and its largest shareholder, CEO Kim So-yeon, disclosed that they signed a mandate agreement with a domestic securities firm for a third-party share issuance and a sale of the controlling stake, aimed at improving governance and management transparency, with the mandate reportedly remaining valid until the investment and share sale are completed.

The KOSDAQ Market Committee finalized a delisting resolution in September 2025, but an injunction filed by the company has put liquidation-trading and related delisting procedures on hold, making the eventual court ruling on the merits a key variable for whether delisting proceeds.

According to one report (THE VC, as of May 2026), the Seoul Rehabilitation Court reportedly decided to commence receivership proceedings and set a deadline for submission of a reorganization plan; because this has not yet been confirmed through formal disclosure, the actual approval status and debt-adjustment terms require separate verification.

The same report cited preliminary first-quarter figures of roughly 4.9 billion won in consolidated revenue, an operating loss of about 4.0 billion won, and a net loss of about 4.4 billion won, along with an accumulated deficit of 32.2 billion won as of end-March, but these should also be treated as provisional, unconfirmed figures.

The company is exploring new collaborations beyond its core diagnostics business, including discussions with Myongji Hospital on a smart blood bank and a plasma-derived medicinal product facility, though no confirmed timeline for revenue contribution exists.

On the clinical-trial falsification allegations, the company issued a statement shortly after a National Assembly audit denying the allegations, and regulatory and legal uncertainty is likely to persist until the related investigation and administrative processes reach a final conclusion.

Ultimately, the sequence and outcomes of three near-term events—court approval of a reorganization plan, execution of a change-of-control agreement, and the court's ruling on the delisting injunction—will largely determine the company's future form.

Valuation

PER

—

PBR

—

ROE

—

EPS

-₩16,917

BPS

—

Dividend per share

₩0

PCL has not generated profit in recent years, making conventional earnings-based valuation metrics difficult to apply, and based on official exchange data, the share price reflects a meaningful premium over net asset value per share.

This suggests the market is pricing in expectations or uncertainty tied to the outcome of the receivership and change-of-control process more than the company's current book net-asset scale.

However, because the stock has been under trading suspension since the delisting review began, the price currently observed should be interpreted with caution as to whether it reflects normal supply and demand.

The company has not paid a dividend through its most recent fiscal year, so dividend-based metrics offer little additional support for valuation.

Because total equity itself has shrunk substantially over the past year, whether new capital is injected through an approved reorganization plan or a change-of-control transaction remains a variable that could again affect net asset value per share and its relationship to price going forward.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05

Bull factors

Potential debt restructuring through receivership

Court receivership temporarily limits individual creditor claims and provides an opportunity to restructure the balance sheet through debt adjustment.

Reports indicate the Seoul Rehabilitation Court decided to commence receivership proceedings, which, if carried through, could help reduce the accumulated deficit and debt burden. This remains contingent on final court approval and creditor consent, and has not yet been confirmed through formal disclosure.

Prospect of new capital via change-of-control sale

The company and its largest shareholder disclosed a mandate agreement with a securities firm for a change of control via third-party share issuance and a stake sale. If a new investor is finalized, this could bring in new capital alongside a restructuring of governance.

However, signing a mandate does not guarantee deal completion, and the identity of the investor and deal terms require confirmation through future disclosures.

Narrow profitability in recent quarters

In the first and third quarters of 2025, despite a small revenue base, both operating income and net income turned narrowly positive. This suggests some cost-structure adjustment may have taken hold.

However, the second quarter of the same year swung back to a large loss, and the trailing four-quarter total remains a large net loss, warranting caution in reading the trend.

Bear factors

Risk that delisting procedures resume

The KOSDAQ Market Committee finalized a delisting resolution in September 2025, and the company's injunction has only paused procedures such as liquidation trading, not reversed the delisting decision itself.

If the court denies the injunction or the company loses on the merits, delisting procedures, including liquidation trading, could resume. The stock is already under trading suspension, constraining investors' ability to secure liquidity.

Core product approval revocation and legal risk

The Ministry of Food and Drug Safety revoked the manufacturing approval for the company's COVID-19 saliva self-test kit effective December 24, 2025, in connection with clinical-trial falsification allegations, following an earlier prosecutorial investigation referral and a police notification confirming the allegations.

The company has denied the allegations, but additional legal risk, including potential damages claims, remains until the investigation and administrative processes reach a final conclusion.

Collapse of the revenue base and capital erosion

Annual revenue fell for three consecutive years, from about 37.2 billion won in 2022 to 1.2 billion won in 2024, and controlling-shareholder equity declined sharply over the same period. Operating cash flow deficits have also widened each year, creating a structural reliance on external funding.

Without a normalization of revenue, achieving financial stability without further capital raising or restructuring appears difficult.

Risk factors

Listing status risk

The delisting decision has only been temporarily stayed by a court injunction, not reversed, so liquidation trading and delisting could resume depending on the litigation outcome.

Reports have also cited additional administrative-issue designation triggers, such as failure to file quarterly reports, meaning compliance with periodic disclosure obligations is itself a risk factor. A prolonged trading suspension also constrains investors' ability to trade or mark positions.

Legal and regulatory risk

The clinical-trial falsification allegations led to a prosecutorial investigation referral, a police notification confirming the allegations, and revocation of product approval by the drug regulator.

Related investigations or administrative litigation may still be ongoing, and the outcome could result in additional sanctions or damages liability. The company denies the allegations, leaving substantial uncertainty until a final determination is reached.

Financial and going-concern risk

With capital impairment and a sharp revenue decline occurring simultaneously, the company is unable to improve its financial structure on its own and is pursuing receivership and a change-of-control sale at the same time. If either process fails, funding could be cut off, threatening the company's continued existence.

Multiple variables, including the identity of a new investor, court approval of a reorganization plan, and the terms of any debt restructuring, remain unresolved.

What to watch next

Around mid-September 2026
Investors should verify through official disclosures whether the reported deadline (September 16) for submitting the reorganization plan is met and whether the court grants approval.
When the ruling on the underlying delisting-injunction lawsuit is announced
Whether liquidation trading and delisting procedures resume will hinge on whether the court sides with the company, so the timing and content of the ruling need to be checked.
When a disclosure on the third-party share issuance and stake-sale agreement is made
Investors should check the specific terms of the change-of-control transaction, including the identity of the new investor, the size of funds raised, and resulting ownership changes.
At the time of the next periodic filing (annual or quarterly report)
Since a past failure to file reports added to the administrative-issue designation grounds, investors should confirm whether periodic filings resume normally and check the latest confirmed revenue and earnings figures.
When follow-up action from the drug regulator or investigative authorities on the clinical-trial falsification allegations is announced
The final outcome of the criminal investigation and administrative action will determine the scale of the company's legal risk, so related announcements should be monitored.

Overall view

PCL has experienced three consecutive years of steep revenue decline following the fading of pandemic-era demand, accumulating large operating losses and capital erosion, compounded by regulatory and legal risk stemming from the revocation of its core product's approval and clinical-trial falsification allegations.

The KOSDAQ Market Committee resolved to delist the company in September 2025, and with procedures stayed pending the company's injunction, the stock remains under trading suspension, leaving its listing status uncertain.

The company is simultaneously pursuing court receivership and a change of control via third-party share issuance and stake sale in an effort to remain viable, though neither process has yet reached a final conclusion.

The narrow profit turnaround in the third quarter of 2025 is notable, but viewed alongside the large loss in the second quarter of the same year and the deeply negative trailing four-quarter net result, it is difficult to characterize this as a definitive improving trend.

From a valuation standpoint, earnings-based metrics are difficult to apply, and the price-to-book relationship also needs to be interpreted with the trading suspension in mind.

Investors should track, in sequence, the progress of four events: approval of a reorganization plan, execution of a change-of-control agreement, the court's ruling on the delisting matter, and the normalization of periodic disclosures.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.